AngioDynamics (ANGO) Tops Q2 EPS by 2c; Reaffirms

AngioDynamics (NASDAQ: ANGO) reported Q2 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $85.4 million versus the consensus estimate of $84.38 million.

GUIDANCE:

Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum